Drug Science is the leading independent scientific body on drugs in the UK. We work to provide clear, evidence-based information without political or commercial interference.

By Rayyan Zafar an Honorary Research Assistant for Drug Science Can a ‘double standard’ in paediatric medicine provide a framework to restructure repressive medical cannabis policies? In 2019, a drug called Zolgensma came to market. This drug used a particularly innovative gene therapy technique to treat infants suffering with an extremely…

The Contradictions of Ketamine: results from a new clinical trial treating alcohol use disorder - Prof Celia Morgan Celia Morgan is a Professor of Psychopharmacology and Head of Psychology at the University of Exeter. She started researching ketamine at UCL for her PhD with Val Curran over twenty years ago and…

Prohibition has failed to reduce drug-related deaths and unregulated stimulant drugs such as cocaine and MDMA pose a significant risk to public health. These is more often than not due to contamination and uncontrolled dosage. In this webinar, Steve Rolles and Roz Gittins explain how we could regulate a stimulant market…

Job brief We are now recruiting a Study Coordinator (Part-time) to join our team. The Study Coordinator will support the efficient and successful delivery of Project Twenty21, acting as a central liaison for all key stakeholders.  They will provide operational support to the team, assisting with prescriber on-boarding, patient acquisition and…

As clinical trials reveal more evidence for the therapeutic potential of psychedelic drugs such as psilocybin, DMT, and even entheogens like MDMA, many psychedelic companies have sprung up to develop psychedelic drugs for specific applications. With promising results in the treatment of mental health conditions such as depression, addiction, anxiety, and…